236 related articles for article (PubMed ID: 8392219)
1. Cancer-associated antigen CA 195 in patients with mucinous ovarian tumours: a comparative analysis with CEA, TATI and CA 125 in serum specimens and cyst fluids.
de Bruijn HW; ten Hoor KA; Boonstra H; Marrink J; Krans M; Aalders JG
Tumour Biol; 1993; 14(2):105-15. PubMed ID: 8392219
[TBL] [Abstract][Full Text] [Related]
2. Tumour-associated trypsin inhibitor (TATI) in human ovarian cyst fluid. Comparison with CA 125 and CEA.
Halila H; Huhtala ML; Haglund C; Nordling S; Stenman UH
Br J Cancer; 1987 Aug; 56(2):153-6. PubMed ID: 3117086
[TBL] [Abstract][Full Text] [Related]
3. Improved specificity of the CA 125 enzyme immunoassay for ovarian carcinomas by use of the ratio of CA 125 to carcinoembryonic antigen.
Wu JT; Miya T; Knight JA; Knight DP
Clin Chem; 1988 Sep; 34(9):1853-7. PubMed ID: 2458203
[TBL] [Abstract][Full Text] [Related]
4. Tumour-associated trypsin inhibitor (TATI) in ovarian cancer.
Halila H; Lehtovirta P; Stenman UH
Br J Cancer; 1988 Mar; 57(3):304-7. PubMed ID: 3162682
[TBL] [Abstract][Full Text] [Related]
5. CA 125 and carcinoembryonic antigen levels in cyst fluid, ascites and serum of patients with ovarian neoplasms.
Harłozińska A; Bar JK; Gawlikowski W; Richter R; Cisło M
Ann Chir Gynaecol; 1991; 80(4):368-75. PubMed ID: 1667567
[TBL] [Abstract][Full Text] [Related]
6. TATI (tumour-associated trypsin inhibitor) as a marker of ovarian cancer.
Medl M; Ogris E; Peters-Engl C; Leodolter S
Br J Cancer; 1995 May; 71(5):1051-4. PubMed ID: 7734298
[TBL] [Abstract][Full Text] [Related]
7. The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis.
Gadducci A; Ferdeghini M; Prontera C; Moretti L; Mariani G; Bianchi R; Fioretti P
Gynecol Oncol; 1992 Feb; 44(2):147-54. PubMed ID: 1312052
[TBL] [Abstract][Full Text] [Related]
8. Tumor-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in patients with epithelial ovarian cancer.
Peters-Engl C; Medl M; Ogris E; Leodolter S
Anticancer Res; 1995; 15(6B):2727-30. PubMed ID: 8669854
[TBL] [Abstract][Full Text] [Related]
9. Tumor-associated trypsin inhibitor (TATI) in benign and malignant gastric disease.
Loizate Toricaguena A; Lamiquiz Vallejo A; Dominguez Merru-Urrutia MJ; Legorburu Escudero JF
Scand J Clin Lab Invest Suppl; 1991; 207():59-62. PubMed ID: 1780694
[TBL] [Abstract][Full Text] [Related]
10. Tumour-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian tumours.
Mogensen O; Mogensen B; Jakobsen A
Br J Cancer; 1990 Feb; 61(2):327-9. PubMed ID: 2310684
[TBL] [Abstract][Full Text] [Related]
11. Tumour-associated trypsin inhibitor (TATI) in patients with colorectal cancer: a comparison with CEA, CA 50 and CA 242.
Pasanen P; Eskelinen M; Kulju A; Penttilä I; Janatuinen E; Alhava E
Scand J Clin Lab Invest; 1995 Apr; 55(2):119-24. PubMed ID: 7667604
[TBL] [Abstract][Full Text] [Related]
12. A study of cyst fluid and plasma carcinoembryonic antigen in patients with cystic ovarian neoplasms.
van Nagell JR; Pletsch QA; Goldenberg DM
Cancer Res; 1975 Jun; 35(6):1433-7. PubMed ID: 805659
[TBL] [Abstract][Full Text] [Related]
13. Serum tumor markers CEA, CA 50, TATI, and NSE in lung cancer screening.
Järvisalo J; Hakama M; Knekt P; Stenman UH; Leino A; Teppo L; Maatela J; Aromaa A
Cancer; 1993 Mar; 71(6):1982-8. PubMed ID: 8443749
[TBL] [Abstract][Full Text] [Related]
14. Tumor-associated trypsin inhibitor (TATI) in patients with colorectal carcinoma. A critical comparison with CEA.
Catarino M; Conde R
Scand J Clin Lab Invest Suppl; 1991; 207():43-6. PubMed ID: 1780689
[TBL] [Abstract][Full Text] [Related]
15. The value of estimating CA 125 in fluids from benign or malignant cysts, in the exudate and blood serum in women with ovarian cancer.
Markowska J; Kopczyński Z; Szewierski Z; Markowski M; Niecewicz R
Eur J Gynaecol Oncol; 1994; 15(1):29-32. PubMed ID: 8206067
[TBL] [Abstract][Full Text] [Related]
16. Tumor markers CA 125, carcinoembryonic antigen and tumor-associated trypsin inhibitor in patients with cervical adenocarcinoma.
Leminen A
Gynecol Oncol; 1990 Dec; 39(3):358-63. PubMed ID: 2258083
[TBL] [Abstract][Full Text] [Related]
17. Comparison of tumor-associated trypsin inhibitor (TATI) with CA125 as a marker for diagnosis and monitoring of epithelial ovarian cancer.
Gadducci A; Ferdeghini M; Rispoli G; Prontera C; Bianchi R; Fioretti P
Scand J Clin Lab Invest Suppl; 1991; 207():19-24. PubMed ID: 1780685
[TBL] [Abstract][Full Text] [Related]
18. Tumor-associated trypsin inhibitor in pancreatic diseases.
Aroasio E; Piantino P
Scand J Clin Lab Invest Suppl; 1991; 207():71-3. PubMed ID: 1723534
[TBL] [Abstract][Full Text] [Related]
19. Serum tumor markers and cyst fluid analysis are useful for the diagnosis of pancreatic cystic tumors.
Sperti C; Pasquali C; Guolo P; Polverosi R; Liessi G; Pedrazzoli S
Cancer; 1996 Jul; 78(2):237-43. PubMed ID: 8673998
[TBL] [Abstract][Full Text] [Related]
20. Tumor-associated trypsin inhibitor, TATI, in gastrointestinal cancer and related benign diseases.
Piantino P; Arosaio E
Scand J Clin Lab Invest Suppl; 1991; 207():67-9. PubMed ID: 1780697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
